Leaderboards/Treatment of Major Depression

Treatment of Major Depression

Last updated June 1, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Yanbo Zhang
University of Saskatchewan
73

Rising Stars Papers

1
Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats
Scientific Reports|2025
2 cit.
2
Psilocybin Mitigates Behavioral Despair and Cognitive Impairment in Treatment-resistant Depression Model using Wistar Kyoto Rats
Research Square|2025
0 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Yuki Arai
Gunma University
99
2
Zitong Wang
University of Alberta
99
3
Gregor Berger
University Hospital of Zurich
87
4
Hannah M. Jester
Wake Forest University
73
5
Shuhui Wang
Inner Mongolia Medical University
68
6
Jiachi Xu
Central South University
58
7
Lee Chi-Wei
National Yang Ming Chiao Tung University
51
8
E. D. Kasyanov
St.Petersburg V.M.Bekhterev Psychoneurological Research Institute
50
9
Yingliang Dai
The University of Melbourne
48
10
Bryan Shapiro
University of California, Irvine Medical Center
40

Emerging Leaders Papers

1
Lifetime Prevalence of Recurrent and Persistent Depression: A Scoping Review of Epidemiological Studies
Clinical Practice and Epidemiology in Mental Health|2025
7 cit.
2
Towards an expanded neurocognitive account of ketamine’s rapid antidepressant effects
The International Journal of Neuropsychopharmacology|2025
5 cit.
3
Esketamine reduces postoperative depression in breast cancer through TREK-1 channel inhibition and neurotransmitter modulation
Cancer Cell International|2025
3 cit.
4
Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats
Scientific Reports|2025
2 cit.
5
Fluoxetine substitution for deprescribing antidepressants: a technical approach
Journal of Psychiatry and Neuroscience|2025
2 cit.
6
Effectiveness and safety of esketamine in laparoscopic surgery patients: a systematic review and meta-analysis of randomized controlled trials
Frontiers in Pharmacology|2025
2 cit.
7
Duloxetine deteriorates prefrontal noradrenergic pain facilitation, but reduces locus coeruleus activity to restore endogenous analgesia in chronic neuropathic pain state
Scientific Reports|2025
1 cit.
8
Overactive Neuronal eEF2K/eEF2 signaling is associated with cognitive impairment and apathy-like behavior
Molecular Psychiatry|2025
1 cit.
9
STAT3 Signaling Mediates Agomelatine Restoration of Prefrontal Cortex Synaptic Plasticity in Chronic Social Defeat Stress Mice
Molecular Neurobiology|2025
1 cit.
10
ω-3 Fatty Acids in Pediatric Major Depressive Disorder
JAMA Network Open|2026
1 cit.

All-Time Leaders

The canon

All-Time Leaders Researchers

1
John Geddes
University of Oxford
99
2
Todd D. Gould
University of Maryland, Baltimore
97
3
Alan F. Schatzberg
Stanford University
91
4
Baoman Li
China Medical University
91
5
Jordi Alonso
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
88
6
Peng Xie
Chongqing Medical University
78
7
Angela Roberts
University of Cambridge
77
8
Pierre Baumann
University of Lausanne
77
9
Paul Stokes
King's College London
73
10
Frans G. Zitman
EMGO Institute for Health and Care Research
70

All-Time Leaders Papers

1
Overweight, Obesity, and Depression
Archives of General Psychiatry|2010
4.3k cit.
2
Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis
The Lancet|2018
3.4k cit.
3
Major depressive disorder
Nature Reviews Disease Primers|2016
2.1k cit.
4
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Pharmacopsychiatry|2017
1.4k cit.
5
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Pharmacological Reviews|2018
1.2k cit.
6
Screening for Depression in the General Population with the Center for Epidemiologic Studies Depression (CES-D): A Systematic Review with Meta-Analysis
PLoS ONE|2016
966 cit.
7
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Signal Transduction and Targeted Therapy|2024
844 cit.
8
The dopamine theory of addiction: 40 years of highs and lows
Nature reviews. Neuroscience|2015
653 cit.
9
Prefrontal cortex and depression
Neuropsychopharmacology|2021
580 cit.
10
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
Journal of Neuroinflammation|2022
478 cit.

Reagents for Treatment of Major Depression

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Cell Signaling Technology

Bak (D4E4) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 350 Conjugate)

#17316$458
View Evidence →Cell Signaling Technology

Nucleolin (E5M7K) Mouse Monoclonal Antibody

#87792$156
View Evidence →Cell Signaling Technology

Phospho-Cyclin D1 (Thr286) Antibody

#2921
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Coronin 1A (D6K5B) Rabbit Monoclonal Antibody (Alexa Fluor® 647 Conjugate)

Cited in 14 papers
#65356$465
View Evidence →Cell Signaling Technology

GATA-4 (D3A3M) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 350 Conjugate)

Cited in 10 papers
#31948$458
View Evidence →Cell Signaling Technology

MZB1 (E8V4N) Rabbit Monoclonal Antibody

Cited in 5 papers
#96905$161
View Evidence →